Free Trial

PureTech Health (LON:PRTC) Trading Down 12.4% - Here's What Happened

PureTech Health logo with Medical background

PureTech Health plc (LON:PRTC - Get Free Report) shares were down 12.4% during trading on Thursday . The stock traded as low as GBX 100.40 ($1.32) and last traded at GBX 103 ($1.36). Approximately 3,018,245 shares traded hands during mid-day trading, an increase of 192% from the average daily volume of 1,035,028 shares. The stock had previously closed at GBX 117.60 ($1.55).

Analyst Upgrades and Downgrades

Separately, Jefferies Financial Group restated a "buy" rating and set a GBX 455 ($6.00) price target on shares of PureTech Health in a research note on Monday, December 16th.

Read Our Latest Research Report on PRTC

PureTech Health Stock Performance

The stock has a 50-day moving average price of GBX 134.79 and a 200-day moving average price of GBX 147.92. The firm has a market capitalization of £373.67 million, a PE ratio of -5.10 and a beta of 1.02. The company has a debt-to-equity ratio of 45.82, a current ratio of 3.68 and a quick ratio of 2.51.

PureTech Health Company Profile

(Get Free Report)

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.

Recommended Stories

Should You Invest $1,000 in PureTech Health Right Now?

Before you consider PureTech Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.

While PureTech Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Palantir’s Big Week Reveals a Rare Growth Story in a Shaky Market
Buy the Fear: 3 Down Stocks That Could 10x Your Profits
Congress Bought THESE Stocks as Tariffs Tanked the Market

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines